Mesothelioma in Situ With a TP53 Mutation

Andrew Churg1, Erika Haase2, Raheela Siddiqui3

  • 1Department of Pathology, Vancouver General Hospital, and University of British Columbia, Vancouver, BC, Canada.

Insights

This study details a rare peritoneal mesothelioma case linked to a TP53 gene deletion. P53 overexpression suggests its potential role in diagnosing mesothelioma in situ.

Area of Science:

  • Oncology
  • Genetics
  • Pathology

Background:

  • Mesothelioma in situ (MIA) is a precursor to invasive mesothelioma.
  • Most MIA cases feature BAP1 mutations.
  • The genetic landscape of MIA is not fully understood.

Purpose of the Study:

  • To report a unique case of MIA progressing to invasive mesothelioma.
  • To investigate the genetic alterations associated with this specific MIA case.
  • To explore the potential diagnostic utility of p53 in MIA.

Main Methods:

  • Case study of a 55-year-old male patient.
  • Immunohistochemistry for BAP1, MTAP, NF2/merlin, and p53.
  • Analysis of a long in-frame TP53 deletion.

Main Results:

  • The patient presented with peritoneal mesothelioma.
  • Immunohistochemistry revealed retained BAP1, MTAP, and NF2/merlin.
  • Overexpression of p53 was observed in MIA and invasive mesothelioma.
  • A long in-frame TP53 deletion was identified.

Conclusions:

  • This is the first reported case of MIA associated with a TP53 mutation.
  • TP53 alterations may play a role in MIA development and progression.
  • p53 immunohistochemistry may aid in the diagnosis of mesothelioma in situ.